Fulgent Genetics, a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, completed the acquisition of CSI Laboratories, a cancer testing and diagnostics laboratory. Financial terms were not disclosed. "We are extremely excited to add CSI Laboratories’ expertise and team to the Fulgent family. Their high standards for test quality and customer service fit extremely well with our values and culture at Fulgent. We look forward to adding their extensive oncologic and molecular diagnostic testing capabilities to our platform," Ming Hsieh, Fulgent Chairman and CEO.